Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

Corneal Transplantation Clinical Trial

Official title:

UV Light-mediated Corneal Crosslinking as (Lymph)Angioregressive Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05870566
• Other study ID #: Uni-Koeln-5045
• Secondary ID: 01KG2127
• Status: Recruiting
• Phase: N/A
• Start date: November 20, 2023
• Est. completion date: September 30, 2028

Study information

• Verified date: December 2023
• Source: University of Cologne
• Contact: Claus Cursiefen, Prof. Dr.
• Phone: 00492214784300
• Email: marie.seifert[@]uk-koeln.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.

Description:

Multicenter, two armed, controlled, open randomised parallel-group study to evaluate the effect of corneal crosslinking as pre-treatment vs. no pre-treatment ahead of full-thickness penetrating corneal transplantation.

After screening of inclusion and exclusion criteria, eligible subjects will be included after obtaining informed consent. Randomisation will be performed at a 5:4 ratio.

At the baseline assessment, a slit lamp examination and photo documentation as well as LaserFlareCellMeter (if available), corneal tomography, and Slit lamp Adapted Optical Coherence Tomography (SL-OCT) measurements will be performed. In addition, visual acuity and a vision-related quality of life will be assessed.

In the intervention arm, the study intervention (CXL) will then be administered to reduce CoNV 10-8 weeks prior to corneal transplantation. Two weeks after CXL a control will be performed including AE documentation, slit lamp examination, SL-OCT, corneal tomography, visual acuity and photo documentation. The study intervention will be repeated once if insufficient (less than 50%) reduction of CoNV should be observed (4 weeks after first CXL at the earliest and 4 weeks prior to corneal transplantation at the latest). All subjects in the intervention arm will then be scheduled for corneal transplantation.

In the control arm, subjects will be directly scheduled for corneal transplantation. Corneal transplantation will be performed as standard full-thickness penetrating procedure, and the graft (7.75 mm in diameter) will be secured with 16-24 interrupted single or double running 10-0 nylon single sutures (decision by the surgeon).

Postoperatively, follow-up assessments will be performed at 3, 6, 12, 18, and 24 months for all subjects and every 6 months thereafter until the end of the trial. A slit lamp examination, AE and photo documentation as well as LaserFlareCellMeter (if available), corneal tomography, SL-OCT, and corneal endothelial cell count measurements will be performed. In addition, visual acuity and a vision-related quality of life will be assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: September 30, 2028
• Est. primary completion date: September 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically prevascularized cornea with need for corneal transplantation

• Written informed consent by subject and/or witness/legal representative, prior to any study-related procedures

• Adult male and female subjects = 18 years old

• = 2 corneal quadrants covered by pathological corneal neovascularization

• Absence of other clinical contraindications to any part or product of the treatment plan

• A cooperative attitude to follow up the study procedures

Exclusion Criteria:

• < 2 corneal quadrants covered by pathological neovascularization

• Corneal stromal thickness below 400 µm

• Active or suspected intraocular inflammation

• Active corneal ulceration

• Compromised eyelid mobility and/or symblepharon

• Allergy, sensitivity or intolerance to riboflavin or UV

• Contraindications to the local or systemic antibiotics and/or corticosteroids foreseen by the protocol

• Contraindications to the surgical protocol

• Clinically significant or unstable concurrent disease or other medical condition affecting grafting procedure

• Rheumatic diseases

• Subjects unlikely to comply with the study protocol

• Participation in another clinical trial where an investigational drug was received less than 4 weeks prior to screening visit

• Positive for human immunodeficiency virus (HIV)

• Known abuse of alcohol, drugs, or medicinal products

• Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the subject's compliance, or place the subject at high risk of complications related to the treatment

• Employees of the sponsor, or employees or relatives of the investigator.

• Pregnant women and nursing mothers as corneal transplantation in standard care is performed under general anesthesia

• Persons held in an institution by legal or official order

Related Conditions & MeSH terms

• Corneal Transplantation

Intervention

Device:
• Corneal Crosslinking
Riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device with maximal diameter of 11 mm will be used. Additionally, the limbal area will be protected by a custom-cut limbal stell cell protection shield.

Locations

Country	Name	City	State
Germany	University Hospital of Cologne, Centre for Ophthalmology	Cologne	NRW

Sponsors (4)

Lead Sponsor	Collaborator
Claus Cursiefen	German Federal Ministry of Education and Research, Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik, Uniklinik Köln, Zentrum für Klinische Studien

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	First episode of endothelial graft rejection	Endothelial graft rejection episode is defined by at least 2 of the following criteria: new endothelial precipitates, new anterior chamber cells/flare, focal or diffuse new edema of the graft. All signs will be analyzed by slit lamp examination, on standardized digital slit lamp pictures, by LaserFlareCellMeter (if available), SL-OCT and corneal tomography.	within 24 months after transplantation
Secondary	Regression of CoNV	Regression of CoNV assessed by morphometrical analysis of the corneal area covered by CoNV using digital standardized slit lamp images and an independent reading center (CORIC)	prior to and 2-4 weeks after each CXL, prior to transplantation and at 3, 6, 12, 18 and 24 months
Secondary	Regression of CoNV	Number of CXL procedures needed for >50% regression of CoNV	before transplantation
Secondary	Recurrence of CoNV	Recurrence of CoNV after CXL and after transplantation	after CXL and 3, 6, 12, 18 and 24 months after transplantation
Secondary	Overall functional graft survival rate	Functional survival of graft will be assessed at every follow-up visit after transplantation clinically and using digital slit lamp pictures, SL-OCT and corneal tomography (for graft thickness) as well as endothelial cell counts.	3, 6, 12, 18 and 24 months after transplantation
Secondary	Absence of rejection-related graft failure	Assessed at every follow-up visit after transplantation: defined according to the respective criteria for graft rejection and associated graft failure (yes: no evidence of endothelial graft rejection, survival of the graft OR no evidence of endothelial graft rejection, failure of the graft; no: endothelial graft rejection, failure of the graft)	3, 6, 12, 18 and 24 months after transplantation
Secondary	Best corrected visual acuity (BCVA)	BCVA assessed using ETDRS charts (logMAR transformed)	Prior to CXL, prior to transplantation and after 3, 6, 12, 18, and 24 months
Secondary	Vision-related quality of life	Overall score measured using the NEI-VFQ25	Prior to CXL, prior to transplantation and after 3, 6, 12, 18, and 24 months
Secondary	Active infectious keratitis or corneal ulceration	Clinical assessment by slit lamp examination	every study visit
Secondary	Graft dehiscence	Graft dehiscence with leakage of aqueous humor from the graft/host interface, assessed by slit lamp examination	3, 6, 12, 18 and 24 months after transplantation
Secondary	Delayed epithelial wound healing	assessed by slit lamp examination	3, 6, 12, 18 and 24 months after transplantation